Secarna Establishes Oncology Advisory Board with Experts Prof. Dr. Eggermont and Prof. Dr. Zippelius

Secarna Pharmaceuticals GmbH & Co. KG has formed a Scientific Advisory Board focused on oncology by appointing Prof. Dr. Alexander M.M. Eggermont and Prof. Dr. Alfred Zippelius. The SAB will guide the development of lead compound SECN-15 and other oncology projects. Prof. Eggermont, recognized internationally in cancer drug development, will work alongside Prof. Zippelius, who has advised Secarna since 2016.

The SAB aims to offer scientific advice as Secarna advances SECN-15, an antisense therapeutic targeting Neuropilin 1, to IND-enabling studies. SECN-15 has potential as a first-in-class therapeutic, modulating tumor-promoting functions. The expertise of Eggermont and Zippelius is expected to be invaluable in this process.

Alexander Gebauer, CEO of Secarna, expressed enthusiasm about the appointments. Eggermont and Zippelius also shared their commitment to supporting Secarna's efforts in developing targeted cancer therapies.